Windtree Therapeutics, a Nasdaq-listed biotech firm, announced plans to purchase up to $700 million in BNB cryptocurrency after it hit a new all-time high price. To fund these purchases, the company is raising $520 million, which includes a $500 million equity line of credit and a $20 million stock-purchase agreement. The CEO emphasized the importance of securing additional funds to enhance their crypto strategy. BNB, ranking as the fifth-largest digital coin with a market cap of $106.9 billion, was recently trading around $769. The firm previously announced a plan to acquire $200 million in BNB, highlighting a growing trend among publicly traded companies to invest in cryptocurrencies to boost their stock value. Recent announcements include other companies, like Nano Labs, planning significant investments in BNB, reflecting a broader interest in crypto treasury strategies among corporations.

Source đź”—